How is Pfizer planning for future growth?

Pfizer is investing in its pipeline, particularly through the acquisition of obesity biotech Metsera and developing new obesity injection treatments.

What are Pfizer's cost-saving goals?

Pfizer is implementing cost-cutting measures aimed at reducing expenses by approximately $7.7 billion by the end of 2027.

Home / Business and Economy / Pfizer Tops Q4 Estimates Amidst Declining Covid Sales

Pfizer Tops Q4 Estimates Amidst Declining Covid Sales

Q: Did Pfizer exceed fourth-quarter expectations?

Yes, Pfizer reported fourth-quarter financial results that surpassed analyst expectations.

3 Feb

•

Summary

Pfizer exceeded fourth-quarter revenue expectations despite lower Covid product demand.
The company is investing in obesity biotech Metsera for future growth.
Pfizer aims to achieve $7.7 billion in cost savings by the end of 2027.

Pfizer Tops Q4 Estimates Amidst Declining Covid Sales

Pfizer reported fourth-quarter financial results that surpassed analyst expectations, even as sales of its Covid-related products continued to decline. The company achieved revenue of $17.56 billion for the quarter, a slight decrease from the previous year, primarily due to reduced demand for its Covid vaccine and Paxlovid antiviral. Despite a reported net loss of $1.65 billion for the quarter, adjusted earnings per share came in at 66 cents, exceeding market predictions.

Looking ahead, Pfizer reaffirmed its 2026 financial guidance, projecting adjusted profit between $2.80 and $3 per share and revenue ranging from $59.5 billion to $62.5 billion. This outlook anticipates largely flat sales compared to 2025, with a significant drop of about $1.5 billion expected for Covid products. An additional $1.5 billion sales decrease is attributed to key drugs losing market exclusivity, including competition for its pneumonia vaccine Prevnar.